Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Hepatitis Health Center

Font Size

New Hepatitis C Drugs Looking Better


The international trial showed that people infected with the hard-to-treat type should be encouraged to stick with high-dose ribavirin for the full 48 weeks of combination treatment. People with easier-to-treat types of the hepatitis C virus get excellent results when they shorten treatment to 24 weeks, even if they take a lower dose of ribavirin as part of the combination therapy. And some of these patients may need only 12 weeks of treatment.

"We are getting close, at least, to the ability to have early predictors of response," Jensen says. "In patients who are having a good response, we don't have to continue. We can stop at 12 weeks and only continue in patients in whom the likelihood of sustained viral response is not as high."

The findings are very reassuring. However, many doctors who treat hepatitis C infection already are treating patients differently depending on the type of virus they carry. Curt H. Hagedorn, MD, is director of hepatology at Atlanta's Emory University.

"Three years ago, a lot of us weren't looking at the type of virus," Hagedorn tells WebMD. "But now it is standard, because people with genotypes 2 and 3 get only 24 weeks of treatment. If they are having toxicities, we consider pressing on in those patients because they have such a high long-term response. We are being much more careful about giving full doses of ribavirin. It is very toxic."

Hagedorn notes that doctors are getting better at treating these toxic effects so that patients can complete their treatments.

And not everybody suffers all of the toxic effects. Bill Kenney, a 47-year-old maintenance supervisor from Chicago, was one of the patients treated in the Jensen study. He was infected with the harder-to-treat genotype 1 form of hepatitis C virus.

"I started treatment on New Year's Day 1999," Kenney says. "By week 12 I was negative for the virus. I've been negative ever since. The side effects were very mild. I did have insomnia, but the nausea and aches and fever and chills I just did not get. ... I finished treatment at Thanksgiving that year and have been negative ever since. I feel tremendously grateful and very lucky."

1 | 2

Today on WebMD

Hepatitus C virus
Types, symptoms and treatments.
liver illustration
Myths and facts about this essential organ.
woman eating apple
What you need to know.
doctor and patient
What causes it?
Hepatitis C Treatment
Syringes and graph illustration
liver illustration
passport, pills and vaccine
Scientist looking in microscope
Fatty Liver Disease
Digestive Diseases Liver Transplantation
Picture Of The Liver
Image Collection